In the wake of a drub­bing, Vivek Ra­maswamy gam­bles $116M on Ar­bu­tus’ hep B work

Over the last few weeks Ar­bu­tus $ABUS has shared a pos­i­tive snap­shot of da­ta from a mid-stage study of its he­pati­tis B ther­a­py and en­joyed a boost from Al­ny­lam’s big suc­cess with its late-stage study of patisir­an, an RNAi drug that us­es its de­liv­ery tech­nol­o­gy and may well spawn a roy­al­ty flow for the biotech. And to­day it’s adding to the streak of good news with the an­nounce­ment that Roivant’s Vivek Ra­maswamy — al­ready an in­vestor — is buy­ing deep­er in­to the com­pa­ny, in­vest­ing $116.4 mil­lion at a pre­mi­um rate to ac­quire pre­ferred shares in Ar­bu­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER